249th ACS Denver, CO – March 22-26, 2015
August 1, 2014 – IntelliSyn awarded NRC-Canada grant to provide medicinal chemistry for the discovery and development of new cancer treatments that target hypoxia response.
Fragment-Based Drug Discovery, Punta Cana. IntelliSyn will be presenting recent results in a presentation entitled: “Extending the range of fragment methodologies: Applications in the absence of crystallography”.
June 23-25. Bio-2014, San Diego, California
Mastering Medicinal Chemistry, Boston, Massachusetts. IntelliSyn will present on the following: “Development of highly potent, selective BET bromodomain inhibitors that are CNS penetrant and effective in rodent models of brain cancer.”
Drug Discovery Chemistry Conference San Diego. We will be presenting our developments in the discovery of CNS penetrant bromodomain inhibitors for GBM and metastatic brain cancer.
April 1, 2014 – IntelliSyn successfully reaches its milestone with Epigenetix and partners its BRD4 inhibitor project with the NeoMed Institute to advance to clinical trials. http://www.neomed.ca/images/pdf/NEOMED_Epigenetix_April1_En.pdf
Miami 2014 Winter Symposium “The Molecular Basis of Brain Disorders” in Miami, Florida
July 1, 2013 – IntelliSyn expands to new facilities at the NeoMed Institute the Montreal Technopark. It is a first-tier R&D facility that has been specifically designed for early R&D work. The building is state-of-the-art and fully equipped for chemistry, biology or drug metabolism studies.
April 26, 2013 – IntelliSyn receives NSERC grant in collaboration with Prof. N. Moitessier of McGill University to advance “Novel molecular scaffolds as anti-cancer drug candidates”.